Psychiatric issues in solid organ transplantation

Harvard Review of Psychiatry

Volumn 17, Issue 6, 2009, Pages 398-406

  Heinrich, Thomas W ^a   Marcangelo, Michael ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Anxiety; Depression; Immunosuppressant medications; Organ transplantation; Psychiatry

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CALCINEURIN INHIBITOR; CITALOPRAM; CLONAZEPAM; CYCLOSPORIN; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEFAZODONE; PAROXETINE; PREDNISONE; RAPAMYCIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANXIETY DISORDER; CEREBRAL BLINDNESS; COMORBIDITY; DELIRIUM; DEPRESSION; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; IRRITABILITY; KIDNEY GRAFT; LIAISON PSYCHIATRY; LIVING DONOR; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL INFORMATION; MENTAL DISEASE; MOOD DISORDER; MORBIDITY; MORTALITY; NEUROTOXICITY; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT CARE; PERSONALITY DISORDER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; TREMOR;

COMORBIDITY; COOPERATIVE BEHAVIOR; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERDISCIPLINARY COMMUNICATION; LIVING DONORS; MENTAL DISORDERS; ORGAN TRANSPLANTATION; PATIENT CARE TEAM; POSTOPERATIVE CARE; PSYCHIATRY; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; REFERRAL AND CONSULTATION; TISSUE DONORS;

EID: 72049132384     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673220903463259     Document Type: Review

References (54)

1. Weisbord SD, Kimmel PL. Health-related quality of life in the era of erythropoietin. Hemodial Int 2008;12:6-15.
2. United Network of Organ Sharing. Designated transplant program criteria. http://www.unos.org/policiesandBylaws2/bylaws/UNOSByLaws/pdfs/bylaw120.pdf
3. Dew MA, Roth LH, Thompson ME, Kormos RL, Griffith BP. Medical compliance and its predictors in the first year after heart transplantation. J Heart Lung Transplant 1996;15:631-645
4. DiMartini A, Twillman R. Organ transplantation in paranoid schizophrenia: two case studies. Psychosomatics 1994;35:159-164
5. Levenson JL, Olbrisch MR. Psychosocial evaluation of organ transplant candidates: a comparative survey of the process, criteria, and outcomes in heart, liver and kidney transplantation. Psychosomatics 1993;34:314-323
6. DiMartini A, Weinrieb R, Fireman M. Liver transplantation in patients with alcohol and other substance use disorders. Psychiatr Clin North Am 2002;25:195-209.
7. Gedaly R, McHugh PP, Johnston TD, et al. Predictors of relapse to alcohol and illicit drugs after liver transplantation for alcoholic liver disease. Transplantation 2008;86:1090-1095
8. Nickels M, Jain A, Sharma R, et al. Polysubstance abuse in liver transplant patients and its impact on survival outcome. Exp Clin Transplant 2007;5:680-685
9. Pfitzman R, Schwenze J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007;13:197-205.
10. De Gottardi A, Spahr L, Gelez P, et al. A simple score for predicting alcohol relapse after liver transplantation. Arch Intern Med 2008;167:1183-1188
11. Koch M, Banys P. Liver transplantation and opioid dependence. JAMA 2001;285:1056-1058
12. Botha P, Peaston R, White K, et al. Smoking after cardiac transplantation. Am J Transplant 2008;8:866-871
13. Levenson J, Olbrisch ME. Psychosocial screening and selection of candidates for organ transplantation. In: The transplant patient. Trzepacz PT, DiMartini AF, eds. Cambridge: Cambridge University Press, 2000: 21-41.
14. Organ Procurement and Transplantation Network. Survival by donor type (deceased vs. living). 2009. At http://optn.transplant.hrsa.gov/latestData/ step2.asp?(Category=Survival;Organ=All;SurvivalType=Patient).
15. Rodrigue JR, Pavlakis M, Danovitch GM. Evaluating living kidney donors: relationship types, psychosocial criteria, and consent processes at US transplant programs. Am J Transplant 2007;7:2326-2332
16. Gentry SE, Segev DL, Simmerling M,Montgomery RA. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant 2007;7:2361-2370
17. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004;5:157-167
18. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am 2005;89:649-687
19. De Geest S, Borgermans L,Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995;59:340-347
20. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical mortality and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999;18:549-562
21. Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are there predictors for post transplant noncompliance? A literature overview. Transplantation 2000;70:711-716
22. Shapiro PA, Williams DL, Foray AT, Gelman IS, Wukich N, Sciacca R. Psychosocial evaluation and prediction of compliance problems andmortality after heart transplant. Transplantation 1995;60:1462-1466
23. Cukor D, Newville H, Jindal R. Depression and immunosuppressive medication adherence in kidney transplant patients. Gen Hosp Psychiatry 2008;30:316-317
24. Trzepacz PT, DiMartini A, Tringali R. Psychopharmacologic issues in organ transplantation. Part I: Pharmacokinetics in organ failure and psychiatric aspects of immunosuppressants and anti-infectious agents. Psychosomatics 1993;34:199-207.
25. Fireman M, Di Martini AF, Armstrong SC, Cozza KL.Med-psych drug-drug interactions update. Immunosuppressants. Psychosomatics 2004;45:354-360
26. Drug-induced convulsions; report from the Boston Collaborative Drug Surveillance Program. Lancet 1972;30:677-679
27. Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW. Posterior reversible encephalopathy syndrome after solid organ transplantation. Am J Neuroradiol 2008;29:924-930
28. Nghiem DD. Role of pharmacologic enhancement of P-450 in cyclosporine overdose. Transplantation 2002;74:1355-1356
29. Mrvos R, Hodgman M, Krenzelok EP. Tacrolimus (FK 596) overdose: a report of five cases. J Toxicol Clin Toxicol 1997;35:395-399
30. Wright DH, Lake KD, Bruhn PS, Emery RWJr. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 1999;18:913-915
31. Vella JP, Sayegh MH. Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis 1998;31:320-323
32. Cervelli MJ, RussGR. Itraconazole-tacrolimus drug interaction. Ther Drug Monit 2003;25:483-484
33. Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002;25:707-712
34. Levy GA. Long-term immunosuppression and drug interactions. Liver Transpl 2001;7: S53-9.
35. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58.
36. Bartels OM, Decker O, Harms J, Hauss J, Fangmann J. Changes in quality of life after renal transplant. Transplant Proc 2005;37:1618-1621
37. Dew MA, Roth LH, Schulberg HC, et al. Prevalence and predictors of depression and anxiety-related disorders during the first year after heart transplant.Gen Hosp Psychiatry 1996;18(6 suppl):48S-61S.
38. Dew MA, Kormos RL, DiMartini AF, et al. Prevalence and risk of depression and anxiety-related disorders during the first three years after heart transplantation. Psychosomatics 2001;42:300-313
39. Dobbels F, Skeans MA, Snyder JJ, Tuomari AV, Maclean JR, Kasiske BL. Depressive disorders in renal transplantation: an analysis of Medicare claims. Am J Kidney Dis 2008;51:819-828
40. Ojo, AO, Hanson, JA, Wolfe, RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307-313
41. Limbos MM, Joyce DP, Chan CKN, Kesten S. Psychological functioning and quality of life in lung transplant candidates and recipients. Chest 2000;118:408-416
42. Stukas AA, Dew MA, Switzer GE, DiMartini A, Kormos RL, Griffith BP. PTSD in heart transplant recipients and their primary family caregivers. Psychosomatics 1999;40:212-221
43. Shitrit D, Lev N, Bar Gil-Shitrit, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005;17:658-665
44. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients. Clin Pharmacokinet 2004;43:361-394
45. Carlat DJ. Drug metabolism in psychiatry: a clinical guide. Newburyport, MA: Clearview, 2006.
46. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008;66:76-81.
47. Thase ME. Effects of venlafaxine on blood pressure; a metaanalysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-508
48. Masand P, Tesar G. Use of stimulants in the medicallyill. Psychiatr Clin North Am 1996;19:515-547
49. DeGeest S, Schafer-Keller P, Denhaerynck K, et al. Supporting medication adherence in renal transplantation (SMART): a pilot RCT to improve adherence to immunosuppressive regimens. Clin Transplant 2006; 20:359-368
50. Abbey S, Farrow S. Group therapy and organ transplantation. Int J Group Psychother 1998;48:163-185
51. Baines LS, Joseph JT, Jindal RM. Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants. Kidney Int 2004;65:1937-1942
52. Gross CR, Kreitzer MJ, Reilly-Spong M, Winbush NY, Schomaker EK, Thomas W. Mindfulness meditation training to reduce symptom distress in transplant patients: rationale, design, and experience with a recycled waitlist. Clin Trials 2009;6:76-89.
53. Showalter PE, Young SA, Bilello JF, Schafer TR, Shaver TR. Electroconvulsive therapy for depression in a liver transplant patient. Psychosomatics 1993;34:537.
54. Jayaram G, Casimir A. Major depression and the use of electroconvulsive therapy (ECT) in lung transplant recipients. Psychosomatics 2005;46:244-249